| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
5 analysts have expressed a variety of opinions on Exagen (NASDAQ:XGN) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 2 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $13.2, with a high estimate of $15.00 and a low estimate of $11.00. This upward trend is apparent, with the current average reflecting a 22.79% increase from the previous average price target of $10.75.
A clear picture of Exagen's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mark Massaro | BTIG | Raises | Buy | $13.00 | $11.00 |
| Paul Knight | Keybanc | Raises | Overweight | $15.00 | $12.00 |
| Anderson Schock | B. Riley Securities | Announces | Buy | $15.00 | - |
| Kyle Mikson | Canaccord Genuity | Raises | Buy | $11.00 | $8.00 |
| Paul Knight | Keybanc | Maintains | Overweight | $12.00 | $12.00 |
For valuable insights into Exagen's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Exagen analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Exagen's remarkable performance in 3M is evident. As of 30 June, 2025, the company achieved an impressive revenue growth rate of 14.19%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Exagen's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -25.81% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Exagen's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -32.36%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Exagen's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -8.96% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Exagen's debt-to-equity ratio surpasses industry norms, standing at 1.2. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: XGN
